Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Change in Receivables (2016 - 2025)

Ptc Therapeutics has reported Change in Receivables over the past 14 years, most recently at -$22.2 million for Q4 2025.

  • Quarterly results put Change in Receivables at -$22.2 million for Q4 2025, up 45.5% from a year ago — trailing twelve months through Dec 2025 was $10.2 million (up 686.09% YoY), and the annual figure for FY2025 was $10.2 million, up 686.09%.
  • Change in Receivables for Q4 2025 was -$22.2 million at Ptc Therapeutics, down from $6.5 million in the prior quarter.
  • Over the last five years, Change in Receivables for PTCT hit a ceiling of $47.8 million in Q1 2025 and a floor of -$40.8 million in Q4 2024.
  • Median Change in Receivables over the past 5 years was $3.8 million (2022), compared with a mean of $5.2 million.
  • Peak annual rise in Change in Receivables hit 1166.07% in 2021, while the deepest fall reached 3307.82% in 2021.
  • Ptc Therapeutics' Change in Receivables stood at $16.4 million in 2021, then skyrocketed by 44.78% to $23.7 million in 2022, then plummeted by 135.23% to -$8.3 million in 2023, then plummeted by 388.27% to -$40.8 million in 2024, then skyrocketed by 45.5% to -$22.2 million in 2025.
  • The last three reported values for Change in Receivables were -$22.2 million (Q4 2025), $6.5 million (Q3 2025), and -$21.9 million (Q2 2025) per Business Quant data.